BioVendor | ® Group

Human MxA

Precision in medicine: The Role of MxA in Managing Infections and Immune Responses

– Differentiating viral from bacterial infections

– Detection and assessment of active phase of viral infections

– Immune response assessment

– Autoimmune and inflammatory disease activity marker

– Therapeutic monitoring in interferon therapy

Why to Avoid Overuse of Antibiotics?

Antimicrobial resistance is a global public health challenge, which has been accelerated by the overuse of antibiotics

Increased antimicrobial resistance leads to severe infections, complications, longer hospital stays, and increased mortality.

This issue is particularly prevalent in primary care, where most infections are viral. General practitioners issue about 90% of all antibiotic prescriptions, primarily for respiratory tract infections. Overprescribing antibiotics not only contributes to resistance but also increases the risk of adverse effects and frequent patient re-attendance. Antibiotic overuse issue is not limited to respiratory tract infections in adults; it also significantly impacts vulnerable populations such as newborns.

Effective interventions to reduce antibiotic overuse include improved laboratory tests or reliable rapid point-of-care tests **to reduce diagnostic uncertainty**. Overprescribing antibiotics not only contributes to resistance but also increases the risk of adverse effects and frequent patient re-attendance. In newborns, especially preterm ones, overuse impairs immune system maturation, making them more susceptible to infections and other immune-related conditions. Antibiotics can affect the development and function of T and B cells, crucial for adaptive immunity.

Acute respiratory infections account for 41% of all outpatient antibiotics, with about half being medically unnecessary.[1] Moreover, antibiotic resistance is estimated to cost double compared to antibiotic treatment.[1,2]

Simple, inexpensive tests such as MxA assay that can guide antibiotic prescription in the outpatient setting have been identified as a successful strategy to reduce inappropriate prescription of antibiotics.[3,4,5]

MxA assay can rule out viral infection with up to 95% sensitivity and 94% specificity.[6] As such the assay allows to identify appropriate candidates for antibiotics and reducing errors.[7]

Economic benefits of the MxA test include less outpatient visits, emergency visits, hospitalizations, and reduced costs related to antibiotic resistance.

MxA: A Key Player in the Immune Response to Viral Infections

Human MxA protein (Myxovirus resistance protein 1), encoded by the MX1 gene, is a 76-kDa protein composed of 662 amino acid residues and is a member of the dynamin superfamily of large GTPases. The MxA protein plays a crucial role in antiviral defense within cells, providing protection against a broad range of viruses, including influenza, parainfluenza, measles, coxsackie, hepatitis B, and Thogoto viruses.

The viruses are inhibited by MxA protein at an early stage in their life cycle, soon after host cell entry and before genome amplification.

The human MxA protein is accumulated in the cytoplasm and endoplasmic reticulum. The membrane compartment of endoplasmatic reticulum seems to provide an interaction platform that facilitates viral target recognition. MxA appears to detect viral infection by sensing and trapping nucleocapsid structures, and becoming the viral components unavailable for the generation of new virus particles.

The expression of viral MxA protein is induced exclusively and, in a dose-dependent manner, by IFN-alpha and IFN-beta, but not by IFN-gamma, IL-1, TNF-alpha or other cytokines.[8]

Extracellular space

Virus entry

Cytoplasm

MxA or B

Release of vRNPs in cytoplasm

vRNP transport into the nucleus

MxA or B

Nuclear or cytoplasmic replication cRNA (+)

Nucleus

Replication

vRNA (-)

cRNA (+)

Transcription

Replication

MxA or B

mRNA (+)

vRNA (-)

Transcription

MxA or B

mRNA (+)

Translation

MxA or B

MxA or B

Proteins + vRNA

Budding and release of new virions

Kinetic Features

MxA protein may offer advantages as a laboratory marker because of its very low basal concentration, increasing within 1–2 hours of infection and long half-life being approximately 2–3 days.[9]

In mononuclear cells stimulated with high doses of leukocyte IFN-alpha, MxA mRNA levels increased tenfold within 4 hours, and elevated MxA protein levels persists over the next 48 hours.[8,12]

Kinetic Features of CRP, Procalcitonin, IL-6 and MxA

Biomarker	Time-to-induction	Peak	Half-Life	Clinical Relevance
C-Reactive Protein (CRP)	4–6 hours	48 hours	19 hours	Inflammation, Bacterial and viral infections
Procalcitonin	3 hours	12–24 hours	20–24 hours	Bacterial infections
IL-6	1–2 hours	4–24 hours, upon severity or nature of infection	15 hours	Inflammation, Bacterial and viral infections
MxA (Myxovirus resistance protein A)	1–2 hours	16 hours, and remains increased in the presence of increased IFN	2–3 days	Viral infections, including respiratory viruses

## Bacterial Infections

● MxA   ● CRP   ● PCT   ● IL-6

Viral Infections

Case Report

A patient with COVID-19 was admitted to the unit of intensive care with severe viral respiratory tract infection. A substantial improvement in health status was observed during the hospitalization. MxA, CRP and PCT levels were measured during the hospitalization. The severity of the clinical condition was accompanied by high levels of MxA, while a decrease in MxA was observed when the clinical condition improved. CRP levels showed a delayed response compared to MxA and PCT concentrations indicated the absence of bacterial coinfection.

Blood MxA (ng/ml)

700

600

500

400

300

200

100

Serum CRP (mg/L) and PCT (ng/ml)

120

100

80

60

40

20

0

Day 1 | Day 2 | Day 3 | Day 4 | Day 5

● Blood MxA (ng/ml) ● Serum CRP (mg/L) ● Serum PCT (ng/ml)

New Insights into Clinical Diagnostics

MxA protein with its low basal concentration and long half-life, offers advantages as a marker for viral infection. Clinical studies have reported on MxA protein in peripheral blood mononuclear cells as a marker distinguishing viral from bacterial disease, and as a reliable marker for type I IFN bioavailability during IFN treatment in patients with multiple sclerosis (MS) according to the recommendation from EMA (European Medicine Agency).

1 Differentiating viral from bacterial infections

2 Detection and assessment of active phase of viral infections

3 Immune response assessment

4 Autoimmune and inflammatory disease activity marker

5 Therapeutic monitoring in interferon therapy

1 Differentiating Viral from Bacterial Infections

Elevated MxA levels are more specific to viral infections and help differentiate viral infections from bacterial infections. MxA is useful in clinical practice to avoid unnecessary antibiotic treatments in viral infections. MxA has been particularly studied in the context of respiratory infections, such as influenza and respiratory syncytial virus (RSV), as its levels rise significantly in these conditions.

The frequency of viral infections is 6–8 times more frequent over bacterial infections in newborns or preterm newborns, and antibiotic treatment is overused substantially. Avoid unnecessary antibiotic treatments substantially reduces risks of immunity damage or later autoimmunity disorders development.

2 Detection and Assessment of Active Phase of Viral Infections

MxA expression is significantly upregulated in peripheral blood mononuclear cells in response to type I interferons (IFN-α/β), which are typically produced in response to viral infections, or directly by viruses. Therefore, measuring MxA levels help identify viral infections, even when the specific virus is not easily detectable.

3   Immune Response Assessment

MxA serves as a marker for assessing the
overall immune response capability, particularly
in immunodeficiencies or after organ transplantations.

4   Autoimmune and Inflammatory Disease Activity Marker

In diseases such as systemic lupus erythematosus
(SLE), which are linked to the pathogenesis of type I
interferons, MxA levels reflect disease activity

and can monitor disease progression or response
to treatment.

5   Therapeutic Monitoring in Interferon Therapy

In patients receiving interferon therapy, such as those
with multiple sclerosis[10] or certain cancers, MxA levels
can be monitored to assess the treatment's efficacy.
An increase in MxA indicates a response to therapy.
2–40% percent of MS patients develop IFN-beta
neutralizing antibodies (NAb) with subsequent
attenuation of MxA protein induction. MxA assay can
be used for assessment of raised NAb according to

the recommendation from EMA (European Medicine
Agency).

MxA levels were monitored in 10 patients with multiple
sclerosis treated with IFN-1b over 24 months after
initiating the therapy. Two patients showed low MxA
levels after 24 months, indicating a poor response
to IFN, and were advised for the drug replacement.

Blood MxA level

M0 M3 M6 M9 M12 M15 M19 M21 M24

Ineffective therapy
drug replacement
is recommended

Recommended routine determination of MxA

Evaluation of the biological activity of recombinant IFN beta-1a from two manufacturers using the MxA assay. The comparison indicates that Drug1 is more potent than Drug2, with approximately three times the dose of Drug2 required to achieve the same effect as Drug1.[11]

European Medicines Agency (EMA) Guidelines Suggesting The Use of MxA

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) released the guideline on clinical requirements for interferon beta (IFN-β) containing medicinal products in 2013: EMA/CHMP/BMWP/652000/2010

Pharmacokinetics
Serum concentrations of IFN-β are very low after the administration of therapeutic dosages and their measurement is technically difficult. Possible methods of detection include a cell-based myxovirus resistance protein A (MxA) induction assay, which measures the biological activity of IFN-β in serum samples, and ELISA assays, which determine the IFN-β protein mass.

Pharmacodynamics
MxA induction can be measured from peripheral blood leukocytes both at the protein and mRNA level; it is currently considered as one of the most sensitive markers of the biological activity of type I interferons and should be one of the selected markers.

Clinical safety
It is recommended that the standardised MxA protein assay or a NAb assay that has been validated against the MxA protein is used for clinical safety of IFN-β (EMEA/CHMP/BWP/580136/2007).

Who Can Benefit from MxA Assay?

Patients

with upper respiratory tract infections

Blood Biobank

for screening donors

Hospitals

for monitoring organ transplant recipients, and preoperative and/or postoperative investigations

Private Medical Care Centres

with travel and tropical medicine department for screening blood-borne tropical viral-origin fevers, such as dengue fever, malaria, or yellow fever

Specialized Healthcare Centres

for conditions Sjögren's Syndrome (applicability of MxA in stratifying patients with primary Sjögren's syndrome according to IFN positivity) and multiple sclerosis (monitoring the efficacy of treatment in patients with multiple sclerosis treated with interferon beta)

Product information

CLIA MxA

Assay Format	Size	Regulatory Status
Chemiluminiscence Immunoassay	50 tests	IVD C€

CL-MxA050

Human MxA POCT

Assay Format	Size	Regulatory Status
Lateral Flow Test	10 tests	IVD C€

BI005-10

Human MxA ELISA

Assay Format	Size	Regulatory Status
Sandwich ELISA, Biotin-labelled Antibody	96-well	RUO

RD194349220R

References

1/ Harris AM, Hicks LA, Qaseem A. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016;164(6):425-434

2/ Ebell MH, Radke T. Antibiotic use for viral acute respiratory tract infections remains common. Am J Manag Car. 2015;21(10):e567-e575

3/ Centers for Disease Control. Antibiotic Resistance Threats in the United States. Published online 2019. Accessed June 16, 2020

4/ Dittrich S, Tadesse BT, Moussy F, et al. Target product profile for a diagnostic assay to differentiate between bacterial and non-bacterial infections and reduce antimicrobial overuse in resource-limited settings: an expert consensus. PLoS ONE. 2016;11(8):e0161721

5/ The Review on Antimicrobial Resistance. Tackling Drug-resistant Infections Globally: Final Report and Recommendations. Published online 2016. Accessed May 21, 2021

6/ Shapiro NI, Self WH, Rosen J, et al. A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever. Ann Med. 2018;50(5):420-429

7/ Dick K, Schneider J. Economic evaluation of FebriDx®: a novel rapid, point-of-care test for differentiation of viral versus bacterial acute respiratory infection in the United States. JHEOR. 2021;8(2)56-62

8/ Ronni T, Melén K, Malygin A, Julkunen I. Control of IFN-inducible MxA gene expression in human cells. J Immunol. 1993 Mar 1;150(5):1715-26

9/ Verhelst J, Hulpiau P, Saelens X. Mx proteins: antiviral gatekeepers that restrain the uninvited. Microbiol Mol Biol Rev. 2013 Dec;77(4):551-66

10/ Glaser A et al. (32 authors), Multiple sclerosis registries in Europe - An updated mapping survey. Mult Scler Relat Disord. 2019 Jan;27:171-178

11/ Shokrollahi Barough M et al.. Neutralizing antibody production against Rebif® and ReciGen® in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability. Int Immunopharmacol. 2018 Sep;62:109-113

12/ Mataki N, Ohmura H, Kodama T, Nakamura S, Kichikawa Y, Nishimura K, Nakai M, Nagura M, Tabata S, Miyoshi K, Sasaki H, Kawano S, Mimura S, Aono S, Ito T, Uwabe Y. Myxovirus resistance protein A in peripheral blood predicts supplemental oxygen need in COVID-19. J Infect. 2021 May;82(5):186-230

Contact us

Product Management
Michal Karpíšek
Scientific Product Manager
+420 549 124 186
karpisek@biovendor.com

BioVendor LM®

BioVendor – Laboratorní medicína a.s.
Karásek 1767/1
621 00 Brno
Czech Republic
+420 549 124 111
info@biovendor.cz
www.biovendor.cz

BioVendor R&D®

BioVendor Research & Diagnostic Products
Karásek 1767/1
621 00 Brno
Czech Republic
+420 549 124 185
info@biovendor.com
www.biovendor.com

TestLine®

TestLine Clinical Diagnostics s.r.o.
Křižíkova 68
612 00 Brno
Czech Republic
+420 549 121 259
sales@testlinecd.com
www.testlinecd.com

DiaSource®

DIASource ImmunoAssays S.A.
Rue du Bosquet, 2,
1348 Louvain-la-Neuve
Belgium
+32 10 84 99 11
info@diasource.be
www.diasource-diagnostics.com

BioVendor Group®

BioVendor Group
Karásek 1767/1
621 00 Brno
Czech Republic

20240801